Blood Cancer Drugs Market 2020 Global Analysis Forecast to 2030 by Key Players | Covid 19 Impact And Recovery

The Business Research Company offers “Blood Cancer Drugs Global Market Report 2020-30: Covid 19 Impact And Recovery" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country. It also compares the market’s historic and forecast growth, and highlights important trend s and strategies that players in the market can adopt.

The global blood cancer drugs market is expected to decline from $21.3 billion in 2019 to $19.3 billion in 2020 at a compound annual growth rate (CAGR) of -9.5%. The decline is mainly due to the COVID-19 outbreak and the measures to contain it. Hospitals across the world have postponed the chemo treatments for cancer patients due to covid positive cases in the hospitals. The sessions are delayed or postponed to prevent patients and staff from unnecessary exposure. The cancer treatment can lower the patient`s ability to fight infection. COVID-19 pandemic is affecting industries across the globe including the pharmaceutical sector. The disruptions due to extended factory closures in various countries, shortage of APIs and other chemicals, rise in prices of key ingredients, and slowed production are the key factors for this decline. The market is then expected to recover and grow at a CAGR of 7.8% from 2021 and reach $29.2 billion in 2023.

Place a DIRECT PURCHASE ORDER of The Entire 140+ Pages Report @ https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2587

The blood cancer drugs market consists of sales of drugs to treat all types of blood cancers. The blood cancer drugs market excludes biologics and includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating leukemia, lymphoma, and myeloma. The blood cancer drugs include Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin) and others

The blood cancer drugs market is being driven by the growing death incidences and increasing prevalence of blood cancer cases across the globe. Different types of blood cancers such as lymphoma, leukemia, myeloma and others have different risk factors where some can be controlled or prevented through drug therapies and others may lead to death.

Blood Cancer Drugs Market Segmentation:
By Blood Cancer Type :
1.Leukemia
2.Lymphoma
3.Myeloma.

By Drugs:
1.Rituaxan/Mabthera (Rituximab)
2.Gleevac/Glivec (Imatinib)
3.Revlimid (Lenalidomide)
4.Velcade (Bortezomib),
5.Tasigna (Nilotinib)
5.Pomalyst (Pomalidomide),
6.Vidaza (Azacitidine)
7.Kyprolis (Carfilzomib)

Browse Complete Report @ https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Few Points From Table Of Content
1. Executive Summary
2. Blood Cancer Drugs Market Characteristics
3. Blood Cancer Drugs Market Size And Growth
4. Blood Cancer Drugs Market Segmentation
5. Blood Cancer Drugs Market Regional And Country Analysis
……
26. Key Mergers And Acquisitions In The Blood Cancer Drugs Market
27. Blood Cancer Drugs Market Trends And Strategies
28. Product Pipeline Analysis
29. Blood Cancer Drugs Market Future Outlook and Potential Analysis
30. Appendix

The report covers the trends and market dynamics of the Blood Cancer Drugs Market in major countries - Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The report also includes consumer surveys and various future opportunities for the market.

Request for a Sample Copy of This Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=2587&type=smp

Some of the key players involved in the Blood Cancer Drugs Market are Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Johnson & Johnson, Novartis, Pfizer Inc, AbbVie Inc., Takeda Pharmaceutical Company Ltd, F.Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc

Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Blog: http://blog.tbrc.info/

About US:
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets after WHO declared COVID-19 as a pandemic.

This release was published on openPR.